Lilly(US:LLY) ZACKS·2024-07-16 22:51Company Overview - Eli Lilly (LLY) shares closed at $941.60, reflecting a -0.93% change from the previous day, underperforming the S&P 500's gain of 0.64% [1] - Over the past month, Eli Lilly's shares have increased by 7.4%, while the Medical sector and S&P 500 gained 0.71% and 3.82%, respectively [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is scheduled for August 8, 2024, with an expected EPS of $2.67, indicating a 26.54% increase from the same quarter last year [1] - Revenue is forecasted to be $9.8 billion, representing a 17.96% growth compared to the prior-year quarter [1] Full Year Projections - Zacks Consensus Estimates predict earnings of $13.61 per share and revenue of $42.85 billion for the full year, reflecting increases of +115.35% and +25.57% from the previous year [2] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for Eli Lilly indicate positive sentiment, as upward revisions often correlate with improved stock price performance [2] - The Zacks Rank system, which evaluates estimate changes, currently ranks Eli Lilly as 3 (Hold) [3] Valuation Metrics - Eli Lilly has a Forward P/E ratio of 69.84, significantly higher than the industry average of 14.97 [3] - The company's PEG ratio stands at 2.1, compared to the industry average PEG ratio of 1.89 [3] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which is part of the Medical sector and holds a Zacks Industry Rank of 106, placing it in the top 43% of over 250 industries [3]